These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 30342077)

  • 21. Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.
    Nounou MI; Adkins CE; Rubinchik E; Terrell-Hall TB; Afroz M; Vitalis T; Gabathuler R; Tian MM; Lockman PR
    Pharm Res; 2016 Dec; 33(12):2930-2942. PubMed ID: 27528392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience.
    Okines A; Irfan T; Khabra K; Smith I; O'Brien M; Parton M; Noble J; Stanway S; Somaiah N; Ring A; Johnston S; Turner N
    Breast J; 2018 May; 24(3):253-259. PubMed ID: 28833867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer.
    Cordero A; Ramsey MD; Kanojia D; Fares J; Petrosyan E; Schwartz CW; Burga R; Zhang P; Rashidi A; Castro B; Xiao T; Lee-Chang C; Miska J; Balyasnikova IV; Ahmed AU; Lesniak MS
    Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34969858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
    Cameron D; Piccart-Gebhart MJ; Gelber RD; Procter M; Goldhirsch A; de Azambuja E; Castro G; Untch M; Smith I; Gianni L; Baselga J; Al-Sakaff N; Lauer S; McFadden E; Leyland-Jones B; Bell R; Dowsett M; Jackisch C;
    Lancet; 2017 Mar; 389(10075):1195-1205. PubMed ID: 28215665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
    Larsen PB; Kümler I; Nielsen DL
    Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
    van Ramshorst MS; van der Heiden-van der Loo M; Dackus GM; Linn SC; Sonke GS
    Breast Cancer Res Treat; 2016 Jul; 158(2):361-71. PubMed ID: 27357813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells.
    Jung Y; Park HJ; Kim PH; Lee J; Hyung W; Yang J; Ko H; Sohn JH; Kim JH; Huh YM; Yun CO; Haam S
    J Control Release; 2007 Nov; 123(2):164-71. PubMed ID: 17854941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inorganic kernel - Supported asymmetric hybrid vesicles for targeting delivery of STAT3-decoy oligonucleotides to overcome anti-HER2 therapeutic resistance of BT474R.
    Shi K; Fang Y; Gao S; Yang D; Bi H; Xue J; Lu A; Li Y; Ke L; Lin X; Jin X; Li M
    J Control Release; 2018 Jun; 279():53-68. PubMed ID: 29655990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer.
    Masuda T; Fujimoto H; Teranaka R; Kuroda M; Aoyagi Y; Nagashima T; Sangai T; Takada M; Nakagawa A; Kubota Y; Yokote K; Ohtsuka M
    Breast Cancer Res Treat; 2020 Apr; 180(3):625-634. PubMed ID: 32124135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantification of Trastuzumab-HER2 Engagement In Vitro and In Vivo.
    Rudkouskaya A; Smith JT; Intes X; Barroso M
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33348564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer.
    You Y; Xu Z; Chen Y
    Drug Deliv; 2018 Nov; 25(1):448-460. PubMed ID: 29405790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models.
    Teranaka R; Fujimoto H; Masuda T; Kuroda M; Aoyagi Y; Nagashima T; Takada M; Sakakibara J; Yamada H; Yamamoto H; Kubota Y; Ohtsuka M
    Breast Cancer; 2023 Nov; 30(6):1018-1027. PubMed ID: 37612442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
    Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
    Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy.
    Singla H; Kalra S; Kheterpal P; Kumar V; Munshi A
    Curr Cancer Drug Targets; 2017; 17(4):344-356. PubMed ID: 27993117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.
    Morikawa A; Wang R; Patil S; Diab A; Yang J; Hudis CA; McArthur HL; Beal K; Seidman AD
    Clin Breast Cancer; 2018 Oct; 18(5):353-361. PubMed ID: 29337140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer.
    Ishida M; Kagawa S; Shimoyama K; Takehara K; Noma K; Tanabe S; Shirakawa Y; Tazawa H; Kobayashi H; Fujiwara T
    Mol Cancer Ther; 2016 Mar; 15(3):402-11. PubMed ID: 26832799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
    Merry CR; McMahon S; Forrest ME; Bartels CF; Saiakhova A; Bartel CA; Scacheri PC; Thompson CL; Jackson MW; Harris LN; Khalil AM
    Oncotarget; 2016 Aug; 7(33):53230-53244. PubMed ID: 27449296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy.
    Jeon SH; Shin KH; Kim JH; Kim K; Kim IA; Lee KH; Kim TY; Im SA
    Breast Cancer Res Treat; 2018 Dec; 172(3):619-626. PubMed ID: 30209731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer.
    Di Modica M; Gargari G; Regondi V; Bonizzi A; Arioli S; Belmonte B; De Cecco L; Fasano E; Bianchi F; Bertolotti A; Tripodo C; Villani L; Corsi F; Guglielmetti S; Balsari A; Triulzi T; Tagliabue E
    Cancer Res; 2021 Apr; 81(8):2195-2206. PubMed ID: 33483370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.